Phase 1b/2 Study of MLN0128 (Dual TORC 1/2 Inhibitor) with Exemestane or Fulvestrant Therapy in Postmenopausal with ER+/HER2- Advanced or Metastatic Breast Cancer that has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestra

Investigator: Hope Rugo, MD
Sponsor: Quintiles, Inc

Location(s): United States


The goal of Phase 1b of this clinical research study is to learn about the safety of MLN0128 when given with exemestane or fulvestrant to patients with breast cancer. The goal of Phase 2 of this study is to learn if MLN0128 given with exemestane or fulvestrant can help to control breast cancer.